Initial staging of localized intermediate to high risk and metastatic prostate cancerInitial staging of younger patientsImprove target delineation for radiation treatment by detecting metabolic lesion(s) and reducing inter‐observer variabilityTreatment response assessment of radiation or systemic treatmentsAssessment of biochemical recurrence post‐treatmentEvaluation for possibility of PSMA radioligand therapiesTargeted biopsy after previous negative biopsy in patients with high suspicion of prostate cancer. The gene discussed is FOLH1; the disease is Familial prostate cancer.